Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT Study: Botensilimab and Balstilimab in Stage II/III Colorectal Cancer with Molecular Residual Disease
NCT07551596Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2027
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botensilimab and balstilimab in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoint: Circulating tumor DNA clearance at 6 months. Planned start May 2027; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07551596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551596.